A Study Using Magnetic Resonance Imaging (MRI) as a Non-invasive Method for Assessing Pancreatic Fibrosis (MINIMAP)

Overview

Información sobre este estudio

The purpose of this study is to evaluate magnetic resonance imaging (MRI) as a non-invasive imaging method to detect chronic pancreatitis (CP) and quantify pancreatic fibrosis.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Enrollment in Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (The PROCEED Study).
  • Participant will be undergoing an MRI of the pancreas for clinical indications OR will be undergoing an MRI of the pancreas for research as part of their participation in the PROCEED Study.
  • All participants must sign an informed consent indicating that they are aware of the investigational nature of this study and are willing to undergo MRI evaluation, and authorizing the use of their protected health information for research purposes.

Exclusion Criteria:

  • Age < 18 or >75 years old.
  • Weight ≥ 350 lbs.
  • Evidence of dense calcific CP, as detected on any abdominal imaging study (the presence of < 10 punctuate calcifications measuring < 3mm is not an exclusion), verified by a CPDPC site radiologist.
  • Presence of >3 cm peri-pancreatic fluid collection.
  • Prior documented allergy to secretin.
  • History of moderate or severe allergic reaction to gadolinium-based contrast agent.
  • Pregnancy.
  • Documented history of inflammatory bowel disease or vagotomy.
  • Active, acute pancreatitis flare.
  • Claustrophobia and/or need for general anesthesia to undergo MRI.
  • History of acute kidney injury within the preceding 6 weeks, with no confirmation that serum creatinine has returned to normal.
  • Known estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2.
  • Severe COPD limiting breath-holding for MRI.
  • Moderate or large volume ascites (of any etiology).
  • Known hemochromatosis.
  • Known cystic fibrosis homozygosity.
  • History of splenectomy.
  • Patients with therapeutic body implants; specifically, pacemakers, defibrillators, or other implanted electronic devices that are not MRI-compatible will be excluded. Patients with an IVC filter, body piercing, neurosurgical clip placement, or shrapnel injury will be evaluated on an individual basis.
  • Unwilling or unable to give written, informed consent.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Santhi Swaroop Vege, M.D.

Cerrado para la inscripción

Contact information:

Vincent Anani

(507) 284-5660

Anani.Vincent@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20450979

Mayo Clinic Footer